Skip to main content
. Author manuscript; available in PMC: 2024 Jul 5.
Published in final edited form as: Prev Med. 2022 May 6;165(Pt B):107079. doi: 10.1016/j.ypmed.2022.107079

Figure 1.

Figure 1.

Cost-effectiveness acceptability curves for the BP+FI vs. BP (panel A) and in the pooled trials (panel B). X-axes show alternative thresholds for cost-effectiveness. Y-axes shows the probability that incentives were cost-effective at that threshold. The curves slope upwards, showing that the higher the threshold, the more likely the intervention will be considered cost-effective.